Pernix Therapeutics Holdings

Rothschild & Co hires Alex Mironov and Matthew O’Donnell as Managing Directors in North America

Retrieved on: 
Monday, August 7, 2023
General Health, Professional Services, Health, Finance, Alvogen, University, Executive officer, Dominic Lee, MBA, Pernix Therapeutics Holdings, U.S. Bancorp, Washington University in St. Louis, Rutgers University, Global Advisory Committee on Vaccine Safety, Business administration, DCM, Rothschild & Co, Ranbaxy Laboratories, Knowledge, Growth, COVI-VAC (U.S. COVID-19 vaccine), ECM, Olin Business School, Therapy, Pfizer, Pharmaceutical industry, Interior design, Health care, Biochemistry

Rothschild & Co announced today that Alex Mironov and Matthew O’Donnell have joined the Healthcare team as Managing Directors.

Key Points: 
  • Rothschild & Co announced today that Alex Mironov and Matthew O’Donnell have joined the Healthcare team as Managing Directors.
  • The senior hires represent the continued growth of the healthcare franchise and expansion of the firm’s presence and capabilities in the Northeast region within the Global Advisory business in North America.
  • They will report to Dominic Hollamby, Partner and Global Head of Healthcare, and Lee LeBrun, Partner and Head of Global Advisory, North America.
  • Mr. Mironov brings over 20 years of global experience in the healthcare and pharmaceutical sectors, spanning business development, M&A and corporate strategy, to Rothschild & Co.

Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer

Retrieved on: 
Monday, October 31, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Board, Biotechnology, Treasury, Leadership, Inflammation, Therapy, VAC2, Forward-looking statement, Geographic atrophy, IPO, Pernix Therapeutics Holdings, NASDAQ, Small business, San Diego Business Journal, U.S. Securities and Exchange Commission, Roche, TASE, Infection, Lineage Cell Therapeutics, RNA, Disease, San Diego State University, Treasurer, Controller, Severe cognitive impairment, Annual report, Accounting, SEC, Auditory neuropathy, Cancer, Security (finance), Compte rendu, Pfizer, Cell, Director, University, Large-cell lung carcinoma, Degenerative disease, GOSS, Hoffmann-La Roche, NYSE American, Nasdaq, Pharma, Growth, Financial Times and McKinsey Business Book of the Year Award, Injury, Howe, Pharmaceutical industry, Genentech, Finance

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Jill Howe will join as the Companys Chief Financial Officer, effective November 14, 2022.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Jill Howe will join as the Companys Chief Financial Officer, effective November 14, 2022.
  • Jill is a wonderful addition to our executive team as we work to establish Lineage as a leader in cell therapy and cell transplant medicine, stated Brian M. Culley, Lineage CEO.
  • Ms. Howe most recently served as Chief Financial Officer of DTx Pharma , a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease.
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

DGAP-News: Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer

Retrieved on: 
Wednesday, March 16, 2022
SEC, Pernix Therapeutics Holdings, Accounting, Multiple sclerosis, Annual report, Private Securities Litigation Reform Act, Controller, Certified Public Accountant, Psoriasis, Risk, Crohn's disease, COVID-19, Nature, CPA, DHODH, Degenerative disease, Primary sclerosing cholangitis, Security (finance), NEW, American Institute of Certified Public Accountants, Clinical trial, Telecommunication, New Jersey Society for the Prevention of Cruelty to Animals, American Institute, Drug development, U.S. Securities and Exchange Commission, Metabolism, Ulcerative colitis, Retail, Pharmaceutical industry, Vaccine, The Immune Response Corporation, Finance

Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer

Key Points: 
  • Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer
    The issuer is solely responsible for the content of this announcement.
  • Announces Promotion of Glenn Whaley, CPAto Chief Financial Officer
    NEW YORK, March 16, 2022 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that Glenn Whaley, CPA, who has served as Vice President Finance, Principal Financial and Accounting Officer since April 2020, has been promoted to the position of Chief Financial Officer.
  • I am honored to lead the finance team as Chief Financial Officer and look forward to continuing to execute on the company's operational and financial goals."
  • In April 2020, he was promoted to Vice President Finance, Principal Financial and Accounting Officer.

Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer

Retrieved on: 
Wednesday, March 16, 2022
SEC, Pernix Therapeutics Holdings, Accounting, Multiple sclerosis, Annual report, Private Securities Litigation Reform Act, Controller, Certified Public Accountant, Psoriasis, Risk, Crohn's disease, COVID-19, Nature, CPA, DHODH, Degenerative disease, Primary sclerosing cholangitis, Security (finance), American Institute of Certified Public Accountants, Clinical trial, Telecommunication, New Jersey Society for the Prevention of Cruelty to Animals, American Institute, Drug development, U.S. Securities and Exchange Commission, Metabolism, Ulcerative colitis, Pharmaceutical industry, Short course immune induction therapy, Finance

Mr. Whaley added, "The milestones achieved in 2021 for both vidofludimus calcium and IMU-935 may result in data that could prove transformative for the company.

Key Points: 
  • Mr. Whaley added, "The milestones achieved in 2021 for both vidofludimus calcium and IMU-935 may result in data that could prove transformative for the company.
  • I am honored to lead the finance team as Chief Financial Officer and look forward to continuing to execute on the company's operational and financial goals."
  • Mr. Whaley joined Immunic as Principal Accounting Officer and Controller in December 2019.
  • In April 2020, he was promoted to Vice President Finance, Principal Financial and Accounting Officer.

LaVoieHealthScience Announces Appointment of Joseph T. Schepers as Senior Vice President of Investor Relations and Financial Communications

Retrieved on: 
Tuesday, November 16, 2021
Marketing, Advertising, Communications, Health, Other Health, Public Relations, Investor Relations, Science, ADR, Novartis, Health, Leadership, Investor relations, NASDAQ, CEO, MBA, Senior, Munich's financial community, ICN, Biotechnology, NYSE, LHS, Seton Hall University, Communication, PR, Public relations, Marketing, Communication, Consulting, Culture Federation, Pernix Therapeutics Holdings, Management

LaVoieHealthScience (LHS), an integrated investor and public relations consulting agency focused on advancing health and science innovations, today announced the appointment of Joseph Joe T. Schepers as Senior Vice President of Investor Relations (IR) and Financial Communications.

Key Points: 
  • LaVoieHealthScience (LHS), an integrated investor and public relations consulting agency focused on advancing health and science innovations, today announced the appointment of Joseph Joe T. Schepers as Senior Vice President of Investor Relations (IR) and Financial Communications.
  • This appointment further strengthens the agencys commitment to integrated strategic communications offering fully integrated public relations, investor relations, marketing, and digital services as well as continued business growth.
  • Mr. Schepers has extensive investor relations and financial communications experience in large cap, mid cap, small cap, and private companies, including positions at Novartis, Immunomedics, Sciele/Shionogi, ICN/Ribapharm, Pernix and Chimerix.
  • Joe has also worked closely with senior management to provide advice and counsel on investor relations and communications strategies related to R&D programs, product launches, and crisis communications.

Seelos Therapeutics Announces Senior Management Appointments

Retrieved on: 
Wednesday, September 1, 2021
Rider University, Amyotrophic lateral sclerosis, LLC, Master of Business Administration, Private Securities Litigation Reform Act, CNS, ALS, Parkinson's disease, Therapy, Major depressive disorder, U.S. Securities and Exchange Commission, Nature, Disease, Business, NPS, Corporate communication, Nasdaq, Sanfilippo syndrome, Psychiatry, SVB Leerink, Shire (pharmaceutical company), ASIB, Central nervous system, Movement disorders, ImClone Systems, MDD, Pernix Therapeutics Holdings, Senior, Post-traumatic stress disorder, Marketing, Patient, CEO, Market for corporate control, Certified Public Accountant, Jefferies, Disorder, Annual report, Business administration, PTSD, Security (finance), Degenerative disease, Pharmaceutical industry, Management

"I congratulate Michael and Anthony on their promotions, which are a testament to their abilities, hard work and dedication to Seelos," said Raj Mehra Ph.D., Chairman and CEO of Seelos.

Key Points: 
  • "I congratulate Michael and Anthony on their promotions, which are a testament to their abilities, hard work and dedication to Seelos," said Raj Mehra Ph.D., Chairman and CEO of Seelos.
  • He was also Vice President of Finance, Principal Accounting Officer and Corporate Controller at Pernix Therapeutics Holdings, Inc., a global commercial life sciences company.
  • Also, during the month of August, several Seelos employees, including certain members of senior management, purchased shares of Seelos stock in the open market.
  • Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases.

Boundless Bio Appoints Jessica Oien as General Counsel and Corporate Secretary

Retrieved on: 
Monday, August 30, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, McCloy, Rolling circle replication, Growth, Therapy, Economics, Verus Pharmaceuticals, Loyola Law School, Research, DNA, Board, Brobeck, Phleger & Harrison, Pernix Therapeutics Holdings, Corporation, North Dakota State University, Élan, Patient, Bio, Â, Milbank, Boundless, General counsel, Pharmaceutical industry, Medical imaging

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that it has appointed Jessica Oien as General Counsel and Corporate Secretary.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that it has appointed Jessica Oien as General Counsel and Corporate Secretary.
  • It is my pleasure to welcome Jessica to our management team as General Counsel and Corporate Secretary, said Zachary Hornby, President and Chief Executive Officer of Boundless Bio.
  • Ms. Oien joins Boundless Bio after serving as General Counsel and Corporate Secretary at the public biotechnology company Cidara Therapeutics.
  • Jessica began her legal career as a corporate associate at Brobeck, Phleger & Harrison and Milbank, Tweed, Hadley & McCloy.

CASI Pharmaceuticals, Inc. To Participate In Jefferies Virtual Healthcare Conference

Retrieved on: 
Thursday, May 27, 2021
Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Health care, Health, Pharmacy, Pernix Therapeutics Holdings, Draft:EntreMed

and BEIJING, May 27, 2021 /PRNewswire/ --CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He, Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the Jefferies Virtual Healthcare Conference.

Key Points: 
  • and BEIJING, May 27, 2021 /PRNewswire/ --CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He, Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the Jefferies Virtual Healthcare Conference.
  • Webcast or external link of the company presentations will be available under "Events & Presentations" in the "Investors Relations" section of CASI's website.
  • CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world.
  • The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., which is located in Beijing, China.

Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference

Retrieved on: 
Wednesday, January 6, 2021
Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Health care, Pharmacy, Health, Pernix Therapeutics Holdings

ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021, at 9:10 a.m.

Key Points: 
  • ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021, at 9:10 a.m.
  • A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com .
  • An archived replay of this webcast will be available for 60 days on the Company's website after the conference.
  • Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Supernus to Participate in Annual Piper Sandler Healthcare Conference

Retrieved on: 
Thursday, November 19, 2020
Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Health care, Health, Pharmacy, Pernix Therapeutics Holdings

ROCKVILLE, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.

Key Points: 
  • ROCKVILLE, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.
  • The Company will also host investor meetings on Thursday, December 3, 2020.
  • An archived replay of this fireside chat will be available for 60 days on the Company's website after the conference.
  • Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.